Financing led by Asabys, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF)

由Asabys领投，CDTI通过其SICC Innvierte项目以及加泰罗尼亚金融研究所（ICF）参与融资

Proceeds will accelerate the expansion of ALLOX’s

所得款项将加速ALLOX的扩张

high-throughput biophysics and AI

高通量生物物理学与人工智能

drug discovery platform and the advancement of a focused pipeline of small molecules against high-value, historically difficult-to-drug

药物发现平台，以及针对高价值、历来难以成药靶点的小分子重点管线的推进

protein-protein interactions and transcription factors

蛋白质-蛋白质相互作用和转录因子

Seasoned biotech executive and investor Morten Graugaard, Co-founder and C

资深生物科技高管兼投资者、联合创始人兼首席...的莫滕·格劳加德（Morten Graugaard）

B

B

O of Orbis Medicines, appointed Independent Chair of the Board

Orbis Medicines 的 O 被任命为董事会独立主席

BARCELONA, Spain, Oct. 29, 2026 (GLOBE NEWSWIRE) -- ALLOX, a biotechnology company developing a high-throughput, experimental-first platform to discover and exploit allosteric sites and other regulatory regions for drug discovery, today announced the successful closing of its US$10.5m (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.

西班牙巴塞罗那，2026年10月29日（环球电讯社）——ALLOX是一家生物技术公司，致力于开发一个以实验为先的高通量平台，用于发现和利用变构位点及其他调控区域以推动药物研发。该公司今日宣布成功完成1050万美元（940万欧元）的种子轮融资，并任命Morten Graugaard为其董事会独立主席。

The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF)..

本轮融资由 Asabys 通过其 Sabadell Asabys II 基金领投，CDTI 通过其 SICC Innvierte 项目以及加泰罗尼亚金融研究所（ICF）参与投资。

The proceeds will be used to scale and expand ALLOX’s platform capabilities and to develop proprietary AI models that predict therapeutic hotspots from the company’s large, function-first biophysical datasets, accelerating the discovery of selective allosteric modulators of protein-protein interactions and transcription factors.

所得资金将用于扩展和增强 ALLOX 的平台能力，并开发专有的人工智能模型，以从其庞大的、功能优先的生物物理数据集中预测治疗热点，从而加速发现针对蛋白质-蛋白质相互作用和转录因子的选择性变构调节剂。

The financing will also strengthen ALLOX’s internal drug discovery team as it advances multiple drug discovery programs towards a focused pipeline of proprietary small-molecule assets, while enabling strategic research collaborations with pharmaceutical and biotechnology partners..

此次融资还将加强ALLOX的内部药物研发团队，推动多个药物发现项目向聚焦的自有小分子资产管线迈进，同时促进与制药和生物技术合作伙伴的战略研究合作。

Morten Graugaard brings more than 20 years of experience across life sciences venture investing, R&D, business development and M&A, as well as building, scaling and running biotech companies. He is currently Chief Business Officer of Orbis Medicines, an AI-first oral biologics company he was instrumental in building and scaling, first as Executive Chair and then as Chief Executive Officer.

莫滕·格劳加德在生命科学领域的风险投资、研发、业务开发与并购，以及生物科技公司的创立、规模扩张和运营方面拥有超过20年的经验。他目前担任Orbis Medicines的首席商务官，这是一家专注于人工智能驱动的口服生物制药公司，他在该公司从执行主席到首席执行官的任期内，为公司的建立和规模扩张发挥了关键作用。

Previously, he was a Partner and Investment Director at Novo Holdings. As Director of Corporate Development at Lundbeck A/S, he led the company’s successful US$658 million acquisition of Chelsea Therapeutics and was a key member of the deal team that negotiated a US$1.8 billion global alliance with Otsuka Pharmaceutical.

此前，他曾担任诺和控股（Novo Holdings）的合伙人兼投资总监。在担任灵北制药（Lundbeck A/S）企业发展总监期间，他主导了公司以6.58亿美元成功收购Chelsea Therapeutics的交易，并作为核心成员参与了与大阪制药（Otsuka Pharmaceutical）谈判达成18亿美元全球联盟协议的交易团队。

Over the past decade, he has held chair, board and advisory roles at several biotechnology companies, including Syndesi Therapeutics, which was acquired by AbbVie for up to US$1 billion in 2022..

在过去十年中，他在多家生物技术公司担任董事长、董事会成员及顾问职务，其中包括于2022年被艾伯维以高达10亿美元收购的Syndesi Therapeutics。

Júlia Domingo, Chief Executive Officer and Co-Founder of ALLOX

朱莉娅·多明戈，ALLOX 首席执行官兼联合创始人

, said:

，说道：

“This financing marks an important milestone, enabling us to advance our internal drug discovery pipeline while expanding the capabilities of our experimental platform and proprietary AI models. By combining large-scale functional data with predictive AI, we aim to unlock a much broader range of challenging drug targets and accelerate the discovery of truly differentiated small-molecule therapeutics.

“此次融资标志着一个重要的里程碑，使我们能够在推进内部药物发现管线的同时，扩展我们的实验平台和专有人工智能模型的能力。通过将大规模功能数据与预测性人工智能相结合，我们旨在解锁更广泛的具有挑战性的药物靶点，并加速真正具有差异化的小分子疗法的发现。”

Morten’s guidance and leadership, along with the support of our investors, will be instrumental in advancing our programs and maximizing the long-term potential of our platform.”.

莫滕的指导与领导，加之我们投资者的支持，将对推动我们的项目以及最大化我们平台的长期潜力起到关键作用。

Morten Graugaard

莫滕·格劳加德

,

，

newly appointed Independent Chair of the Board of ALLOX

新近任命的ALLOX董事会独立主席

, commented:

，评论道：

“ALLOX is addressing one of the most important challenges in drug discovery by unlocking therapeutic opportunities that have historically proven difficult to drug. The team is building a differentiated platform based on high-throughput biophysical data, that stands at the intersection of experimental biology and computation, with the potential to unlock new drug discovery opportunities.

“ALLOX 正在通过解锁历史上难以成药的治疗机会，应对药物发现中最重要的挑战之一。该团队正在构建一个基于高通量生物物理数据的差异化平台，该平台处于实验生物学与计算科学的交叉点，有望开启新的药物发现机遇。”

Importantly, ALLOX fills a critical data gap, enabling the development of functional molecules rather than simply identifying binders. I’m excited to join ALLOX at such a pivotal stage of its development and I look forward to working alongside Júlia, the leadership team and the Board as the company scales its platform and pipeline.”.

重要的是，ALLOX 填补了关键的数据空白，从而能够推动功能分子的开发，而不仅仅是识别结合剂。我很兴奋能在 ALLOX 发展的这一关键阶段加入公司，并期待在公司扩展其平台和研发管线的过程中，与 Júlia、领导团队及董事会携手合作。

Clara Campàs, Co-Founder and Managing Partner at Asabys Partners

克拉拉·坎帕斯，Asabys Partners 联合创始人兼管理合伙人

, noted:

，指出：

“

“

We believe ALLOX is uniquely positioned to expand the scope of druggable biology. The seed financing and Morten’s appointment strengthen both the company’s execution capacity and governance as it advances its platform and begins to translate it into a focused therapeutic pipeline. Given his longstanding track record of success, Morten’s appointment is a huge vote of confidence in ALLOX and its approach.” .

我们相信，ALLOX 在拓展可药物化生物学的边界方面具有独特的优势。种子轮融资的完成以及 Morten 的任命，增强了公司在推进其平台并将其转化为聚焦的治疗产品管线过程中的执行能力和治理水平。鉴于 Morten 长期以来的成功记录，他的加入是对 ALLOX 及其技术路线的巨大信心投票。

ALLOX combines high-throughput genetics, experimental biology and AI to systematically map and discover the functional hotspots that govern protein folding and interactions. By measuring the effects of thousands of mutations in parallel, its platform reveals allosteric, orthosteric and other regulatory sites, including new potential binding pockets.

ALLOX 将高通量遗传学、实验生物学和人工智能相结合，系统地绘制并发现调控蛋白质折叠与相互作用的功能热点。通过并行测量数千种突变的影响，其平台揭示了变构位点、正构位点以及其他调控位点，包括新的潜在结合口袋。

This information can then be leveraged to design targeted small-molecule therapeutics against high-value targets that have historically proven difficult to drug, such as intracellular PPIs and transcription factors..

随后，可以利用这些信息来设计针对高价值靶点的靶向小分子疗法，这些靶点历来被证明难以药物化，例如细胞内蛋白质-蛋白质相互作用（PPIs）和转录因子。

For further information, contact:

如需更多信息，请联系：

Optimum Strategic Communications

奥普蒂姆战略传播

Nick Bastin, Eleanor Cooper, Vareen Outhonesack

尼克·巴斯汀，埃莉诺·库珀，瓦伦·奥索内萨克

+44 20 3821 6170

+44 20 3821 6170

allox@optimumcomms.com

allox@optimumcomms.com

About ALLOX

关于 ALLOX

ALLOX (Allostery Exploration Technologies, S.L.) is a Barcelona-based biotechnology company developing an experimental and AI-enabled platform for the systematic discovery of allosteric drug targets. By combining high-throughput genetics, computational biology and drug discovery, ALLOX aims to identify functional sites in proteins that can unlock new therapeutic approaches for previously difficult-to-drug targets.

ALLOX（Allostery Exploration Technologies, S.L.）是一家总部位于巴塞罗那的生物技术公司，正在开发一个实验性与人工智能赋能的平台，用于系统性地发现变构药物靶点。通过结合高通量遗传学、计算生物学和药物研发，ALLOX 旨在识别蛋白质中的功能位点，从而为以往难以成药的靶点开辟新的治疗途径。

ALLOX is a spin-out of the Centre for Genomic Regulation (CRG) and was co-founded by Professor Ben Lehner, FRS, FMedSci, Head of Generative Genomics at the Wellcome Sanger Institute and a renowned researcher in predictive biology and genetics. For more information, visit .

ALLOX 是基因组调控中心（CRG）的衍生公司，由本·莱纳教授（Ben Lehner，FRS，FMedSci）联合创立。莱纳教授是惠康桑格研究所生成基因组学负责人，也是预测生物学和遗传学领域的知名研究员。欲了解更多信息，请访问。

www.allox.bio

www.allox.bio

.

。

About Asabys Partners

关于 Asabys Partners

Asabys Partners is a Barcelona-based venture capital firm focused on innovation in healthcare and life sciences. With over €400 million in AUM and 24 portfolio companies, Asabys is supported by Alantra and backed by Banc Sabadell as anchor investor. The investment was made through Sabadell Asabys Health Innovation Investments II, FCR, and Sabadell Asabys Health Innovation Investments 2B, SCR, S.A.

Asabys Partners 是一家总部位于巴塞罗那的风险投资公司，专注于医疗保健和生命科学领域的创新。Asabys 的管理资产规模超过 4 亿欧元，拥有 24 家投资组合公司，由 Alantra 提供支持，并由 Banc Sabadell 作为锚定投资者提供背书。该投资是通过 Sabadell Asabys Health Innovation Investments II, FCR 和 Sabadell Asabys Health Innovation Investments 2B, SCR, S.A. 进行的。

This operation benefits from support from the European Union under the InvestEU Fund, through the European Investment Fund (EIF). Find out more at .

本业务受益于欧盟通过欧洲投资基金（EIF）在InvestEU基金下提供的支持。更多信息请访问。

www.asabys.com

www.asabys.com

and follow us on

并在关注我们

LinkedIn

领英

and

和

X

X

.

。

About CDTI

关于 CDTI

The Center for Technological Development and Innovation (CDTI, E.P.E.) is the innovation agency of the Ministry of Science, Innovation, and Universities, dedicated to driving technological innovation across the business sector. The CDTI’s mission is to empower the Spanish business ecosystem to transform scientific and technical knowledge into globally competitive, sustainable, and inclusive growth..

技术创新与发展中心（CDTI, E.P.E.）是西班牙科学、创新与大学部的创新机构，致力于推动企业领域的技术创新。CDTI的使命是赋能西班牙商业生态系统，将科学技术知识转化为具有全球竞争力、可持续且包容性的增长。

INNVIERTE Economía Sostenible SICC S.M.E., S.A. is an initiative created by the CDTI, E.P.E. Its aim is to promote business innovation by supporting venture capital investment in technology-based or innovative companies. This entity, established as part of the Spanish Strategy for Science, Technology, and Innovation, is a closed-end, self-managed collective investment company supervised by the National Securities Market Commission.

INNVIERTE Economía Sostenible SICC S.M.E., S.A. 是由 CDTI, E.P.E. 发起的一项倡议。其宗旨是通过支持对技术型或创新型公司的风险资本投资，促进企业创新。该实体是作为西班牙科学、技术与创新战略的一部分而设立的，是一家受国家证券市场委员会监管的封闭式自我管理集体投资公司。

For further information, please visit .

欲了解更多信息，请访问。

https://www.cdti.es/en

https://www.cdti.es/en

and

和

https://www.innvierte.es/en

https://www.innvierte.es/en

About Institut Català de Finances

关于加泰罗尼亚金融局

The Institut Català de Finances (ICF) is the public financial institution of the Government of Catalonia. Through loans, guarantees and venture capital investment, ICF supports the growth of Catalan companies and the development of strategic and innovative projects.

加泰罗尼亚金融研究所（ICF）是加泰罗尼亚政府的公共金融机构。通过贷款、担保和风险资本投资，ICF支持加泰罗尼亚企业的成长以及战略性和创新性项目的发展。

With a strong track record in financing innovation and technology transfer, ICF plays an active role in the Catalan health and life sciences ecosystem, supporting companies in bringing scientific knowledge and breakthrough technologies closer to the market. Since 1985, ICF has financed more than 37,000 companies, providing over €17 billion in funding..

凭借在融资创新和技术转移方面的卓越业绩，ICF 在加泰罗尼亚健康与生命科学生态系统中发挥着积极作用，支持企业将科学知识和突破性技术更紧密地推向市场。自 1985 年以来，ICF 已为超过 37,000 家公司提供融资，累计资金超过 170 亿欧元。